Comparison of the prognostic significance of Chevallier and Sataloff's pathologic classifications after neoadjuvant chemotherapy of operable breast cancer

Human Pathology

Volumn 39, Issue 8, 2008, Pages 1221-1228

  Penault Llorca, Frederique ^a,b,c   Abrial, Catherine ^a,b   Raoelfils, Ines ^a   Cayre, Anne ^a,b   Mouret Reynier, Marie Ange ^a,c   Leheurteur, Marianne ^a,c   Durando, Xavier ^a,c   Achard, Jean Louis ^a,c   Gimbergues, Pierre ^a,c   Chollet, Philippe ^a,b,c,d  

^a CENTRE JEAN PERRIN   (France)

^b INSERM   (France)

^c UNIVERSITÉ CLERMONT AUVERGNE   (France)

^d Centre d'Investigation Clinique   (France)

Author keywords

Breast cancer; Chevallier's classification; Pathologic complete response; Sataloff's classification

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; NAVELBINE; PACLITAXEL; PIRARUBICIN; TAMOXIFEN; VINCRISTINE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGNOSIS; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; TUMOR CELL; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; PROGNOSIS;

EID: 47549095022     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2007.11.019     Document Type: Article

References (22)

1. Buchholz T., Hunt K., Whitman G., et al. Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks. Cancer 98 (2003) 1150-1160
2. Fisher B., Bryant J., Wolmark N., et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16 (1998) 2672-2685
3. Amat S., Abrial C., Penault-Llorca F., et al. High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast Cancer Res Treat 94 (2005) 255-263
4. Costa S.D., Von Minckwitz G., Raab G., et al. The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer. Semin Oncol 3 Suppl 9 (1999) 24-31
5. Belembaogo E., Feillel V., Chollet P., et al. Neoadjuvant chemotherapy in 126 operable breast cancers. Eur J Cancer 28A (1992) 896-900
6. Chollet P., Charrier S., Brain E., et al. Clinical and pathological response to primary chemotherapy in inoperable breast cancer. Eur J Cancer 33 (1997) 862-866
7. Van Praagh I., Curé H., Leduc B., et al. Efficacy of a primary regimen combining vinorelbine, epirubicin and methotrexate (VEM) as neoadjuvant treatment in 89 patients with operable breast cancer. Oncologist 7 (2002) 418-423
8. Abrial C., Van Praagh I., Delva R., et al. Pathological and clinical response of a primary chemotherapy regimen combining vinorelbine, epirubicin, and paclitaxel as neoadjuvant treatment in patients with operable breast cancer. Oncologist 10 (2005) 242-249
9. Amat S., Bougnoux P., Penault-Llorca F., et al. Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate. Br J Cancer 88 (2003) 1339-1345
10. Amat S., Mouret-Reynier M.A., Penault-Llorca F., et al. Sequential addition of an anthracycline-based regimen to docetaxel as neoadjuvant chemotherapy in patients with operable breast cancer. Clin Breast Cancer 7 (2006) 262-269
11. Abrial C., Mouret-Reynier M.A., Amat S., et al. Tumor parameters, clinical and pathological responses, medical management, and survival through time on 710 operable breast cancers. Med Oncol 22 (2005) 233-240
12. Chevallier B., Roche H., Olivier J.P., et al. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 16 (1993) 223-228
13. Sataloff D.M., Mason B.A., Prestipino A.J., et al. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 180 (1995) 297-306
14. Kaplan E.L., and Meier P. Non parametric estimation from incomplete observation. J Am Stat Assoc 53 (1957) 457-471
15. Kuerer H.M., Newman L., Smith T.L., et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17 (1999) 460-469
16. Carey L.A., Metzger R., Dees E.C., et al. American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome. J Natl Cancer Inst 97 (2005) 1137-1142
17. Rouzier R., Extra J.M., Klijanienko J., et al. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 20 (2002) 1304-1310
18. Chollet P., Amat S., Cure H., et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 86 (2002) 1041-1046
19. Eltahir A., Heys S.D., Hutcheon A.W., et al. Treatment of large and locally advanced breast cancers using neoadjuvant chemotherapy. Am J Surg 175 (1998) 127-132
20. Bonadonna G., Valagussa P., Brambilla C., et al. Primary chemotherapy in operable breast cancer; eight-year experience at the Milan Cancer Institute. J Clin Oncol 16 (1998) 93-100
21. Jones R.L., Lakhani S.R., Ring A.E., et al. Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma. Br J Cancer 94 (2006) 358-362
22. Mazouni C., Peintinger F., Wan-Kau S., et al. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol 25 (2007) 2650-2655